Amivantamab in combination with lazertinib in patients with atypical epidermal growth factor receptor (EGFR) mutations excluding exon 20 insertion mutations: Initial results from CHRYSALIS-2

B.C. Cho; Y. Wang; Y. Li; L. Wu; B. Besse; M.E. Marmarelis; K. Goto; J-S. Lee; S-H. Lee; Y. Zhang; J. Neal; J. Curtin; J.M. Bauml; J. Mahoney; L. Trani; R.E. Knoblauch; P. Tomasini

doi:10.1016/j.annonc.2022.10.359

YUHSpace

BROWSE

0 182

Cited 0 times in

Amivantamab in combination with lazertinib in patients with atypical epidermal growth factor receptor (EGFR) mutations excluding exon 20 insertion mutations: Initial results from CHRYSALIS-2

Authors: B.C. Cho ; Y. Wang ; Y. Li ; L. Wu ; B. Besse ; M.E. Marmarelis ; K. Goto ; J-S. Lee ; S-H. Lee ; Y. Zhang ; J. Neal ; J. Curtin ; J.M. Bauml ; J. Mahoney ; L. Trani ; R.E. Knoblauch ; P. Tomasini